Pfizer, Inc. (PFE)

NYSEHealthcare

$27.38
-$0.18 (-0.7%)
Market closed

February 17, 2026 at 21:00 UTC

Interactive Chart
PFE
1H
3H
6H
12H
1D
1W
1M
3M
6M
1Y
2Y
5Y
All

02:45:32 UTC

About Pfizer, Inc.

Name

Pfizer, Inc.

CEO

Albert Bourla

Industry

Healthcare

Year Founded

1849

Employees

81,000

Pfizer, Inc. is a pharmaceutical company that discovers, develops, and supplies medicines and vaccines used in clinical practice worldwide. The operating model links science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use. Manufacturing and quality systems favor continuity, so once therapies enter practice, supply stays steady. Field teams focus on safety, labeling clarity, and guidance that fits real workflows in hospitals and clinics. Access programs and country teams adapt to local rules while holding to common standards. The goal is simple and long-term: turn evidence into dependable options that clinicians can trust and patients can live with. Within healthcare, Pfizer’s role is to make new treatments feel workable in daily care.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 13 Buy, 7 Hold, 1 Sell
Buy13
Hold7
Sell1
Fundamentals & Financials
Revenue (TTM)
$62.5B
Net Income (TTM)
$7.7B
EPS (TTM)
$1.36
ROA (TTM)
0%
Current Ratio
0
Dividend Yield
0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement
ItemQ4 2025
Revenue$17,557M
Cost of Sales$5,272M
Gross Profit$12,285M
Operating Income$3,688M
Net Income-$1,648M
EPS-$0.29
Technical Indicators

Pfizer, Inc.'s Technical Indicators Summary

Pfizer’s current price sits comfortably above its short and long-term moving averages, reflecting a solid upward trend supported by multiple buy signals from both the 10- and 200-day averages. Momentum indicators such as the CCI and MACD confirm positive momentum, although the RSI and Williams %R suggest a more cautious hold stance. The ADX indicates a moderate trend strength, while the average true range points to stable volatility without significant spikes. Despite this bullish environment, the On-Balance Volume shows a sell signal, highlighting some divergence in volume trends. Overall, the technical picture for Pfizer remains constructive, with price action supported by strong moving averages and momentum indicators.

Buy
13 signals
Neutral
7 signals
Sell
1 signal
Overall: Bullish62% Bullish signals
IndicatorValue
RSI (14)
55.28
Stochastic %K (14, 3, 3)
74.29
CCI (20)
153.37
WPR (14)
-30.51
Momentum (10)
0.47
MFI
60.15
MACD Level (12, 26)
0.08
Bollinger Bands
$24.71 - $25.76
ATR (14)
$0.49 (1.93%)
ADX (14)
20.18
OBV
709,593,300
Exponential Moving Averages
$24.92 - $25.46(5 indicators)
Simple Moving Averages
$24.47 - $25.42(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the bell, PFE was still trading below yesterday, reflecting a -0.761% opening gap down and a close near 27.37. End-of-day, the peer group was roughly unchanged (-0.16%), limiting broader influence on PFE. PFE declined amid limited sector news, with slow pipeline developments weighing on investor sentiment.

Price Change

from $27.58 close

-$0.21

Trading Volume

Below avg (58.1M)

27.8M

vs S&P 500 Today

Moderate Underperformance

-0.36%

52-Week Position

Near highs

91.9%

Updated: February 17, 2026 at 21:17 UTC

Quote Summary
OpenPrevious Close
$27.84$27.58
Day Range52 Week Range
$27.3 - $27.87$20.92 - $27.94
VolumeAvg. Volume
10.9M50.3M
Market CapP/E Ratio
$155.4B20.1